Cargando…
Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma
SIMPLE SUMMARY: This study aimed to investigate the clinical usefulness of comprehensive genomic profiling (CGP) in patients with unresectable hepatocellular carcinoma who received multiple systemic therapies in real-world practice. In this study, all nine patients had gene alterations, and seven we...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913078/ https://www.ncbi.nlm.nih.gov/pubmed/36765676 http://dx.doi.org/10.3390/cancers15030719 |
_version_ | 1784885338348453888 |
---|---|
author | Ishido, Shun Tsuchiya, Kaoru Kano, Yoshihito Yasui, Yutaka Takaura, Kenta Uchihara, Naoki Suzuki, Keito Tanaka, Yuki Miyamoto, Haruka Yamada, Michiko Matsumoto, Hiroaki Nobusawa, Tsubasa Keitoku, Taisei Tanaka, Shohei Maeyashiki, Chiaki Tamaki, Nobuharu Takahashi, Yuka Nakanishi, Hiroyuki Sakurai, Urara Asahina, Yasuhiro Okamoto, Ryuichi Kurosaki, Masayuki Izumi, Namiki |
author_facet | Ishido, Shun Tsuchiya, Kaoru Kano, Yoshihito Yasui, Yutaka Takaura, Kenta Uchihara, Naoki Suzuki, Keito Tanaka, Yuki Miyamoto, Haruka Yamada, Michiko Matsumoto, Hiroaki Nobusawa, Tsubasa Keitoku, Taisei Tanaka, Shohei Maeyashiki, Chiaki Tamaki, Nobuharu Takahashi, Yuka Nakanishi, Hiroyuki Sakurai, Urara Asahina, Yasuhiro Okamoto, Ryuichi Kurosaki, Masayuki Izumi, Namiki |
author_sort | Ishido, Shun |
collection | PubMed |
description | SIMPLE SUMMARY: This study aimed to investigate the clinical usefulness of comprehensive genomic profiling (CGP) in patients with unresectable hepatocellular carcinoma who received multiple systemic therapies in real-world practice. In this study, all nine patients had gene alterations, and seven were candidates eligible for clinical trials based on the results of CGP. The median number of alterations per patient was four, and the blood sample was used in five patients with extrahepatic metastasis. We revealed the genomic information of the patients who received multiple systemic therapies and reported the utility of blood samples in patients with extrahepatic metastasis. Furthermore, the genomic status in patients treated with multiple molecular-targeted agents, including checkpoint inhibitors, would contribute to developing newer systemic agents. ABSTRACT: The molecular mechanism of hepatocellular carcinoma (HCC) is partially demonstrated. Moreover, in the patients receiving multiple molecular-targeted therapies, the gene alternations are still unknown. Six molecular-targeted therapies of unresectable HCC (uHCC) and comprehensive genomic profiling (CGP) have been approved in clinical practice. Hence, the utility of CGP in patients with uHCC treated with multiple molecular-targeted agents is investigated. The data of the patients with uHCC who received CGP tests were collected, retrospectively, between February 2021 and May 2022. Gene alterations detected by foundation testing, excluding variants of unknown significance, were reported in all nine patients. The samples for CGP were derived from liver tumor biopsy (n = 2), surgical specimens of bone metastases (n = 2), and blood (n = 5). The median number of systemic therapies was four. Seven patients were candidates eligible for clinical trials. One patient with a high tumor mutation burden (TMB) could receive pembrolizumab after CGP. This study presented genomic alternations after receiving multiple molecular-targeted therapies. However, further investigation needs to be conducted to develop personalized therapies and invent newer agents for treating HCC. |
format | Online Article Text |
id | pubmed-9913078 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99130782023-02-11 Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma Ishido, Shun Tsuchiya, Kaoru Kano, Yoshihito Yasui, Yutaka Takaura, Kenta Uchihara, Naoki Suzuki, Keito Tanaka, Yuki Miyamoto, Haruka Yamada, Michiko Matsumoto, Hiroaki Nobusawa, Tsubasa Keitoku, Taisei Tanaka, Shohei Maeyashiki, Chiaki Tamaki, Nobuharu Takahashi, Yuka Nakanishi, Hiroyuki Sakurai, Urara Asahina, Yasuhiro Okamoto, Ryuichi Kurosaki, Masayuki Izumi, Namiki Cancers (Basel) Article SIMPLE SUMMARY: This study aimed to investigate the clinical usefulness of comprehensive genomic profiling (CGP) in patients with unresectable hepatocellular carcinoma who received multiple systemic therapies in real-world practice. In this study, all nine patients had gene alterations, and seven were candidates eligible for clinical trials based on the results of CGP. The median number of alterations per patient was four, and the blood sample was used in five patients with extrahepatic metastasis. We revealed the genomic information of the patients who received multiple systemic therapies and reported the utility of blood samples in patients with extrahepatic metastasis. Furthermore, the genomic status in patients treated with multiple molecular-targeted agents, including checkpoint inhibitors, would contribute to developing newer systemic agents. ABSTRACT: The molecular mechanism of hepatocellular carcinoma (HCC) is partially demonstrated. Moreover, in the patients receiving multiple molecular-targeted therapies, the gene alternations are still unknown. Six molecular-targeted therapies of unresectable HCC (uHCC) and comprehensive genomic profiling (CGP) have been approved in clinical practice. Hence, the utility of CGP in patients with uHCC treated with multiple molecular-targeted agents is investigated. The data of the patients with uHCC who received CGP tests were collected, retrospectively, between February 2021 and May 2022. Gene alterations detected by foundation testing, excluding variants of unknown significance, were reported in all nine patients. The samples for CGP were derived from liver tumor biopsy (n = 2), surgical specimens of bone metastases (n = 2), and blood (n = 5). The median number of systemic therapies was four. Seven patients were candidates eligible for clinical trials. One patient with a high tumor mutation burden (TMB) could receive pembrolizumab after CGP. This study presented genomic alternations after receiving multiple molecular-targeted therapies. However, further investigation needs to be conducted to develop personalized therapies and invent newer agents for treating HCC. MDPI 2023-01-24 /pmc/articles/PMC9913078/ /pubmed/36765676 http://dx.doi.org/10.3390/cancers15030719 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ishido, Shun Tsuchiya, Kaoru Kano, Yoshihito Yasui, Yutaka Takaura, Kenta Uchihara, Naoki Suzuki, Keito Tanaka, Yuki Miyamoto, Haruka Yamada, Michiko Matsumoto, Hiroaki Nobusawa, Tsubasa Keitoku, Taisei Tanaka, Shohei Maeyashiki, Chiaki Tamaki, Nobuharu Takahashi, Yuka Nakanishi, Hiroyuki Sakurai, Urara Asahina, Yasuhiro Okamoto, Ryuichi Kurosaki, Masayuki Izumi, Namiki Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma |
title | Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma |
title_full | Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma |
title_fullStr | Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma |
title_full_unstemmed | Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma |
title_short | Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma |
title_sort | clinical utility of comprehensive genomic profiling in patients with unresectable hepatocellular carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913078/ https://www.ncbi.nlm.nih.gov/pubmed/36765676 http://dx.doi.org/10.3390/cancers15030719 |
work_keys_str_mv | AT ishidoshun clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT tsuchiyakaoru clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT kanoyoshihito clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT yasuiyutaka clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT takaurakenta clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT uchiharanaoki clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT suzukikeito clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT tanakayuki clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT miyamotoharuka clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT yamadamichiko clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT matsumotohiroaki clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT nobusawatsubasa clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT keitokutaisei clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT tanakashohei clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT maeyashikichiaki clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT tamakinobuharu clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT takahashiyuka clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT nakanishihiroyuki clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT sakuraiurara clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT asahinayasuhiro clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT okamotoryuichi clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT kurosakimasayuki clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma AT izuminamiki clinicalutilityofcomprehensivegenomicprofilinginpatientswithunresectablehepatocellularcarcinoma |